MedTrace Logo

Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic

NCT07417774 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-02-18

No results posted yet for this study

Summary

The goal of this sub-study of the RESTORE trial is to identify biomarkers associated with tumor hypoxia, identify biomarkers that differentiate pseudoprogression from true progression, and correlate biomarkers with clinical outcomes.

Conditions

  • Glioblastoma (GBM)

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • NuvOx LLC

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-08
Primary Completion
2027-12-31
Completion
2030-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07417774 on ClinicalTrials.gov